| Myrbetriq (mirabegron) / Astellas |
| Active, not recruiting | 1 | 75 | RoW | 50 mg of mirabegron, mirabegron, acupuncture combined with mirabegron. | The Affiliated Ganzhou Hospital of Nanchang University | Overactive Bladder | 03/23 | 12/24 | | |
NCT05767632: Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands) |
|
|
| Completed | 1 | 30 | RoW | Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose), Vesicare & Betmiga, Mirfenacin MR (Solifenacin Succinate 5 mg & Mirabegron 50 mg) (Test), Mirfenacin MR, Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose) | Genuine Research Center, Egypt, Hikma Pharma | Healthy | 07/22 | 10/22 | | |
NCT05992428: Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults |
|
|
| Completed | 1 | 37 | RoW | DA-8010 5mg, Paroxetine 20mg, Mirabegron 50mg | Dong-A ST Co., Ltd. | Healthy | 11/23 | 12/23 | | |
NCT06011265: Does Mirabegron Increase the Body Heat Generated by the Nervous System |
|
|
| Completed | 1 | 19 | US | Myrbetriq 25Mg Extended-Release Tablet, Placebo | Christopher Bell, Indiana University | Thermoregulation | 01/24 | 04/24 | | |
NCT05880862: Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls |
|
|
| Recruiting | 1 | 48 | US | Pelvic Floor Muscle Training, Mirabegron, Myrbetriq, Trospium Chloride | The University of Texas Medical Branch, Galveston, National Institute on Aging (NIA) | Urinary Bladder, Overactive, Urinary Incontinence, Accidental Falls | 12/24 | 07/25 | | |
NCT05634174: ADRB3 Signaling Pathway in Human Adipose Tissue |
|
|
| Recruiting | 1 | 40 | US | Mirabegron, Myrbetriq | University of California, San Diego | Obesity, Prediabetes | 09/25 | 12/25 | | |
NCT03049462: The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists |
|
|
| Recruiting | 1 | 100 | US | Mirabegron, B Complex Plus Vitamin C Tablets | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Polycystic Ovary Syndrome | 09/26 | 09/26 | | |
